title: Plasma cholesterol esterification and transfer, the menopause, and hormone replacement therapy in women.
abstract: With the onset of the menopause, plasma lipids and lipoprotein metabolism changes toward a more atherogenic profile that is improved by HRT. To determine whether cholesterol esterification rate (CER) and transfer of cholesteryl esters from high density lipoproteins to apolipoprotein B-containing lipoproteins are affected by menopause and HRT, plasma newly synthesized cholesteryl ester transfer (NCET) activity, CER and plasma lipids, lipoproteins, and apolipoprotein concentrations were measured in perimenopausal women (age range: 40-55 yr), including 49 premenopausal women and 32 postmenopausal women who were subsequently randomized to receive either placebo or 17-beta estradiol/norethisterone for 6 months. Plasma NCET (P = 0.03) and CER (P = 0.008) were significantly higher in postmenopausal women. Plasma low density lipoprotein cholesterol concentration, high density lipoprotein concentration, and body mass index were independent predictors of plasma NCET in premenopausal women, and plasma triglyceride and apolipoprotein B concentrations were corresponding predictors in postmenopausal women. When data were adjusted for plasma triglyceride, plasma NCET activity was no longer significantly different (P = 0.81) between premenopausal and postmenopausal women. Plasma NCET and CER did not change significantly in postmenopausal women during HRT. These data suggest that the determinants of plasma NCET activity after menopause and increased levels of triglyceride-rich lipoprotein acceptors of cholesteryl esters may lead to increased plasma NCET that is not reduced by HRT in postmenopausal women.
authors.affiliation: Department of Endocrinology and Diabetes, Gloucestershire Royal Hospital, Gloucester, United Kingdom.
authors.forename: N J
authors.initials: NJ
authors.lastname: Lewis-Barned
authors.forename: W H
authors.initials: WH
authors.lastname: Sutherland
authors.forename: R J
authors.initials: RJ
authors.lastname: Walker
authors.forename: H L
authors.initials: HL
authors.lastname: Walker
authors.forename: S A
authors.initials: SA
authors.lastname: De Jong
authors.forename: E A
authors.initials: EA
authors.lastname: Edwards
authors.forename: V H
authors.initials: VH
authors.lastname: Markham
mesh_terms: D000328:Adult; D002352:Carrier Proteins / Q000097:blood*; D002784:Cholesterol / Q000097:blood* / Q000378:metabolism; D053480:Cholesterol Ester Transfer Proteins; D003430:Cross-Sectional Studies; D004951:Esterification; D004958:Estradiol / Q000627:therapeutic use; D015914:Estrogen Replacement Therapy; D005260:Female; D006023:Glycoproteins; D006801:Humans; D008055:Lipids / Q000097:blood; D008593:Menopause / Q000097:blood*; D008875:Middle Aged; D009640:Norethindrone / Q000627:therapeutic use; D017698:Postmenopause / Q000097:blood; D017697:Premenopause / Q000097:blood; D045167:Progesterone Congeners / Q000627:therapeutic use; D016037:Single-Blind Method
chemical_list: C506642:CETP protein, human; D002352:Carrier Proteins; D053480:Cholesterol Ester Transfer Proteins; D006023:Glycoproteins; D008055:Lipids; D045167:Progesterone Congeners; D004958:Estradiol; D002784:Cholesterol; D009640:Norethindrone